Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Zengen, Inc. announces novel approach to reduce organ rejection

17.12.2002


Study in Transplantation provides strong support for the development of therapeutics utilizing company’s proprietary peptide technology



Zengen, Inc. announced today that its scientists have discovered a novel approach to reduce organ rejection based on the Company’s proprietary research with alpha-Melanocyte-Stimulating Hormone (a-MSH). The research shows that treatment with the a-MSH peptide caused a significant increase in allograft (transplanted tissue) survival and a marked decrease in leukocyte (or white blood cell) infiltration, one of the main causes of infection leading to organ rejection. The study entitled, "a-Melanocyte-Stimulating Hormone Protects the Allograft in Experimental Heart Transplantation," appears in the December 15th issue of Transplantation.

"These results demonstrate that the protection of the transplanted tissue from early injury with a-MSH treatment can postpone rejection," said James Lipton, Ph.D., chief scientific officer and director of Zengen. "This is an important and encouraging advance in the field of organ transplantation and these data provide strong support for the development of anti-rejection therapies utilizing our proprietary peptide molecules based on the larger a-MSH peptide."


The preclinical study was designed to determine whether a-MSH treatment protects the allograft and prolongs survival in experimental heart transplantation, in the absence of immunosuppressive therapies. Donor cardiac grafts (Brown Norway) were transplanted into the abdomen of recipient (Lewis) rats. Treatments consisted of intraperitoneal injections of the a-MSH peptide or saline from the time of transplantation until sacrifice or spontaneous rejection.

Results show that median survival time of the peptide-treated organs was significantly prolonged (10 days) as compared to the untreated ones (6 days) (p<0.0001). Histopathologic and gene expression patterns of allografts from treated animals, examined 24 hours after transplantation, revealed substantial benefit over untreated animals and persisted over time. At four days post-transplantation, graft histopathologic appearance was healthier in treated animals. Further, the research revealed that treatment with a-MSH caused a marked inhibition of ET-1 gene expression. ET-1 is the most potent endogenous vasoconstrictor yet identified and contributes to reperfusion injury, transplant rejection and several cardiovascular diseases.

"This is a remarkable increase in duration in non-immunosuppressed transplanted organs, as data from this study and others show that hearts transplanted in these animal models are invariably rejected within six to seven days," added Dr. Lipton. "The beneficial effects of a-MSH treatment observed in these studies could be even more pronounced in clinical transplantation, particularly with regard to its significant role in ET-1 inhibition. We are excited by these findings, especially as we advance our peptide technology program in organ transplantation."


About Zengen, Inc.
Incorporated in 1999, Zengen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent infection and inflammation through application of its proprietary peptide technologies. Zengen’s novel molecules were developed from more than 25 years of original research in the US, Europe and Asia on peptide molecules derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). A naturally occurring molecule, a-MSH modulates inflammatory and immune responses. James Lipton, Ph.D., Zengen’s chief scientific officer, chairman of the scientific advisory board and director, and his collaborators first demonstrated that a-MSH possesses anti-inflammatory properties and uncovered the specific activity of the carboxy-terminal tripeptide region (C-terminal peptide) of the a-MSH peptide. These discoveries led to the development of Zengen’s proprietary peptide molecules, including CZEN 002, a synthetic octapeptide. There is abundant evidence of the anti-inflammatory and anti-infective activity of these novel molecules from both in vivo and in vitro research. Zengen is currently conducting phase I/II clinical trials with CZEN 002 in vaginitis. For more information about Zengen, please visit www.zengen.com.

Zengen, Inc. Forward-Looking Statement Disclaimer

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

Kathy Vincent | EurekAlert!
Further information:
http://www.zengen.com/

More articles from Health and Medicine:

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

nachricht Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Corporate coworking as a driver of innovation

22.11.2017 | Business and Finance

PPPL scientists deliver new high-resolution diagnostic to national laser facility

22.11.2017 | Physics and Astronomy

Quantum optics allows us to abandon expensive lasers in spectroscopy

22.11.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>